Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs

Journal of Lipid Research

Volumn 40, Issue 7, 1999, Pages 1317-1327

  Burnett, John R ^a   Wilcox, Lisa J ^a   Telford, Dawn E ^a   Kleinstiver, Sandra J ^a   Barrett, P Hugh R ^b   Newton, Roger S ^c,d   Huff, Murray W ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PFIZER INC   (United States)

^d Esperion Therapeutics Inc   (United States)

Author keywords

ACAT inhibitor; Apolipoprotein B metabolism; Avasimibe; Kinetics; MRNA

Indexed keywords

APOLIPOPROTEIN B; AVASIMIBE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; IODINE 125; IODINE 131; LEUCINE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; TRIACYLGLYCEROL; TRITIUM; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; LIPID BLOOD LEVEL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SWINE;

ACETATES; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; ENZYME INHIBITORS; FEMALE; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIVER; MALE; STEROL O-ACYLTRANSFERASE; SULFONIC ACIDS; SWINE; SWINE, MINIATURE;

EID: 0032769066     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Suckling, K. E., and E. F. Strange. 1985. Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism. J. Lipid Res. 26: 647-671.
2. Chang, T. Y., C. C. Y. Chang, and D. Cheng. 1997. Acyl-coenzyme A:cholesterol acyltransferase. Annu. Rev. Biochem. 66: 613-638.
3. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362: 801-809.
4. Dixon, J. L., and H. N. Ginsberg. 1993. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J. Lipid Res. 34: 167-179.
5. Yao, Z., and R. S. McLeod. 1994. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. Biochim. Biophys. Acta. 1212: 152-166.
6. Sniderman, A. D., and K. Cianflone. 1993. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler. Thromb. 13: 629-636.
7. Thompson, G. R., R. P. Naoumova, and G. F. Watts. 1996. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res. 37: 439-447.
8. Huff, M. W., and J. R. Burnett. 1997. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr. Opin. Lipidol. 8: 138-145.
9. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
10. Dashti, N. 1992. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells. J. Biol. Chem. 267: 7160-7169.
11. Qin, W., J. Infante, S. Wang, and R. Infante. 1992. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Biochim. Biophys. Acta. 1127: 57-66.
12. Cianflone, K. M., Z. Yasruel, M. A. Rodriguez, D. Vas, and A. D. Sniderman. 1990. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesterol ester synthesis in the response to a fatty acid challenge. J. Lipid Res. 31: 2045-2055.
13. Musanti, R., L. Giorgini, P. Lovisolo, A. Pirillo, A. Chiari, and G. Ghiselli. 1996. Inhibition of acyl-CoA:cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. J. Lipid Res. 37: 1-14.
14. Avramoglu, R. K., K. Cianflone, and A. D. Sniderman. 1995. Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells. J. Lipid Res. 36: 2513-2528.
15. Wilcox, L. J., P. H. R. Barrett, R. S. Newton, and M. W. Huff. 1999. ApoB-100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011; an effect associated with enhanced intracellular degradation of apoB. Arterioscler. Thromb. Vasc. Biol. 19: 939-949.
16. Kulinski, A., D. Dulay, J. Macri, R. Newton, B. Krause, and K. Adeli. 1998. Effects of CI-1011 on the assembly and secretion of apolipoprotein B-containing lipoproteins in HepG2 cells. XIII International Symposium on Drugs Affecting Lipid Metabolism. 76(Abstract)
17. Kosykh, V. A., S. N. Preobrazhensky, I. V. Fuki, A. E. Zaikinal, V. P. Tsibulsky, V. S. Repin, and V. N. Smirnov. 1985. Cholesterol can stimulate secretion of apolipoprotein B in cultured human hepatocytes. Biochim. Biophys. Acta. 836: 385-389.
18. Tanaka, M., H. Jingami, H. Otani, M. Cho, Y. Ueda, H. Arai, Y. Nagano, T. Doi, M. Yokode, and T. Kita. 1993. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes. J. Biol. Chem. 268: 12713-12718.
19. Carr, T. P., R. L. Hamilton, Jr., and L. L. Rudel. 1995. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J. Lipid Res. 36: 25-36.
20. Krause, B. R., M. Anderson, C. L. Bisgaier, T. Bocan, R. Bousley, P. Dehart, A. Essenburg, K. Hamelehle, R. Homan, K. Kieft, W. McNally, R. Stanfield, and R. S. Newton. 1993. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J. Lipid Res. 34: 279-294.
21. Fukushima, H., S. Anono, Y. Nakamura, M. Endo, and T. Imai. 1969. The effect of N-(alpha-methylbenzyl)linoleamide on cholesterol metabolism in rats. J. Atheroscler. Res. 10: 403-414.
22. Heider, J. G., C. E. Pickens, and L. A. Kelly. 1983. Role of acyl-CoA:cholesterol acyltransferase in cholesterol absorption and its inhibition by 57-118 in the rabbit. J. Lipid Res. 24: 1127-1134.
23. Krause, B. R., M. E. Pape, K. Kieft, B. Auerbach, C. L. Bisgaier, R. Homan, and R. S. Newton. 1994. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Arterioscler. Thromb. 14: 598-604.
24. Huff, M. W., D. E. Telford, P. H. R. Barrett, J. T. Billheimer, and P. J. Gillies. 1994. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler. Thromb. 14: 1498-1508.
25. Burnett, J. R., L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R Barrett, and M. W. Huff, 1998. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Biochim. Biophys. Acta. 1393: 63-79.
26. Lee, H. T., D. R. Sliskovic, J. A. Picard, B. D. Roth, W. Wieranga, J. L. Hicks, R. F. Bousley, K. L. Hamelehle, R. Homan, C. Speyer, R. L. Stanfield, and B. R. Krause. 1996. Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering in animals fed noncholesterol-supplemenled diets. J. Med. Chem. 39: 5031-5034.
27. Ramharack, R., M. A. Spahr, C. S. Sekerke, R. L. Stanfield, R. F. Bousley, H. T. Lee, and B. R. Krause. 1998. CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys. Atherosclerosis. 136: 79-87.
28. Krause, B. R., and B. J. Auerbach. 1997. ACAT inhibition by CI-1011 lowers plasma triglycerides in rats by enhancing the clearance of VLDL. Atherosclerosis. 134: 128(Abstr.)
29. Nicolosi, R. J., T. A. Wilson, and B. R. Krause. 1998. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis. 137: 77-85.
30. Koren, M., W. Insull, Jr., H. Schrott, M. Davila, T. Heinonen, R. W. McLain, and D. Black. 1998. ACAT inhibitor avasimibe lowers VLDL and TG in patients with hypertriglyceridemia. Circulation. 98: 1-240(Abstr.)
31. Huff, M. W., D. E. Telford, K. Woodcroft, and W. L. P. Strong. 1985. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs. J. Lipid Res. 26: 1175-1186.
32. Huff, M. W., and D. E. Telford. 1985. Direct synthesis of low-density lipoprotein apoprotein B in the miniature pig. Metabolism. 34: 36-42.
33. Burnett, J. R., L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff. 1997. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apoB production in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 17: 2589-2600.
34. Markwell, M. A. K., S. M. Haas, L. L. Bieber, and N. E. Tolbert. 1978. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87: 206-210.
35. Boomgaardt, J., and B. E. McDonald. 1969. Comparison of fasting plasma amino acid patterns in the pig, rat, and chicken. Can. J. Physiol. Pharmacol. 47: 392-395.
36. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
37. Carr, T. P., C. J. Andresen, and L. L. Rudel. 1993. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin. Biochem. 26: 39-42.
38. Gallo, L. L., J. A. Wadsworth, and G. V. Vahouny. 1987. Normal cholesterol absorption in rats deficient in intestinal acyl coenzyme A:cholesterol acyltransferase activity. J. Lipid Res. 28: 381-387.
39. Azrolan, N., and J. L. Breslow. 1990. A solution hybridization/ RNase protection assay with riboprobes to determine absolute levels of apoB, A-I, and E mRNA in human hepatoma cell lines. J. Lipid Res. 31: 1141-1146.
40. Kieft, K. A., T. M. A. Bocan, and B. R. Krause. 1991. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography. J. Lipid Res. 32: 859-866.
41. Snedecor, G. W., and W. G. Cochran. 1967. The comparison of two samples. In Statistical Methods. G. W. Snedecor and W. G. Cochran, editors. Iowa State University Press, Iowa. 94-97.
42. Sparks, J. D., and C. E. Sparks. 1994. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim. Biophys. Acta. 1215: 9-32.
43. Ginsberg, H. N. 1995. Synthesis and secretion of apolipoprotein B from cultured liver cells. Curr. Opin. Lipidol. 6: 275-280.
44. Sliskovic, D. R., J. A. Picard, P. M. O'Brien, P. Liao, W. H. Roark, B. D. Roth, M. A. Anderson, S. B. Mueller, T. M. A. Bocan, R. F. Bousley, K. L. Hamelehle, R. Homan, J. F. Reindel, R. L. Stanfield, D. Turlock, and B. R. Krause. 1998. Alpha-substituted malonester amides: tools to define the relationship between ACAT inhibition and adrenal toxicity. J. Med. Chem. 41: 682-690.
45. Hainer, J. W., J. G. Terry, J. M. Connell, H. Zyruk, R. M. Jenkins, D. L. Shand, P. J. Gillies, K. J. Livak, T. L. Hunt, and J. R. Crouse III. 1994. Effect of the acyl-CoA:cholesterol acyltransferase DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin. Pharmacol. Ther. 56: 65-74.
46. Pullinger, C. R., J. D. North, B. B. Teng, V. A. Rafici, A. E. Ronhild de Brito, and J. Scott. 1989. The apoB gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J. Lipid Res. 30: 1065-1077.
47. Wu, X., N. Sakata, E. Lui, and H. N. Ginsberg. 1994. Evidence for a lack of regulation of the assembly and secretion of apoliprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester. J. Biol. Chem. 269: 12375-12382.
48. Graham, A., J. L. Wood, and L. J. Russell. 1996. Cholesterol esterification is not essential for secretion of lipoprotein components by HepG2 cells. Biochim. Biophys. Acta. 1302: 46-54.
49. Benoist, F., and T. Grand-Perret. 1996. ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. Arterioscler. Thromb. Vasc. Biol. 16: 1229-1235.
50. Ooyen, C., A. Zecca, T. Zanelli, and A. L. Catapano. 1997. Decreased intracellular degradation and increased secretion of apoB-100 in Hep G2 cells after inhibition of cholesteryl ester synthesis. Atherosclerosis. 130: 143-152.
51. Wu, X., N. Sakata, J. Dixon, and H. N. Ginsberg. 1994. Exogenous VLDL stimulates apolipoprotein B secretion from HepG2 cells by both pre-and post-translational mechanisms. J. Lipid Res. 35: 1200-1210.
52. Fast, D. G., and D. E. Vance. 1995. Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited: evidence for a novel mechanism that regulates VLDL secretion. Biochim. Biophys. Acta. 1258: 159-168.
53. Chang, C. C. Y., H. Y. Huh, K. M. Cadigan, and T. Y. Chang. 1993. Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J. Biol. Chem. 268: 20747-20755.
54. Cases, S., S. Novak, Y. W. Zheng, H. M. Myers, S. R. Lear, E. Sande, C. B. Welch, A. J. Lusis, T. A. Spencer, B. R. Krause, S. K. Erickson, and R. V. Farese, Jr. 1998. ACAT-2, a second mammalian acyl coA: cholesterol acyltransferase: its cloning, expression, and characterization. J. Biol. Chem. 273: 26755-26771.
55. Anderson, R. A., C. Joyce, M. Davis, J. W. Reagan, M. Clark, G. S. Shelness, and L. L. Rudel. 1998. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J. Biol. Chem. 273: 26747-26754.
56. Oelkers, P., A. Behari, D. Cromley, J. T. Billheimer, and S. L. Sturley. 1998. Characterization of two human genes encoding acyl coenzyme A-cholesterol acyltransferase related enzymes. J. Biol. Chem. 273: 26765-26778.
57. Lee, O., C. C. Y. Chang, W. Lee, and T. Y. Chang. 1998. Immunodepletion experiments suggest that acyl-coenzyme A:cholesterol acyl-transferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. J. Lipid Res. 39: 1722-1727.
58. Liscum, L., and K. W. Underwood. 1995. Intracellular cholesterol transport and compartmentation. J. Biol. Chem. 270: 15443-15446.
59. Tabas, I., D. A. Weiland, and A. R. Tall. 1986. Inhibition of acyl coenzyme A: cholesterol acyl transferase in J774 macrophages enhances down-regulation of the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase and prevents low density lipoprotein-induced cholesterol accumulation. J. Biol. Chem. 261: 3147-3155.
60. Jelinek, D. F., S. Andersson, C. A. Slaughter, and D. W. Russell. 1990. Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. J. Biol. Chem. 265: 8190-8197.
61. Kane, J. P., and R. J. Havel. 1995. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, Inc, New York. 1853-1885.
62. Jamil, H., J. K. Dickson Jr., C. Chu, M. W. Lago, J. K. Rinehart, S. A. Biller, R. E. Gregg, and J. R. Wetterau. 1995. Microsomal triglyceride transfer protein. Specificity of lipid binding and transport. J. Biol. Chem. 270: 6549-6554.
63. Wang, S., R. S. McLeod, D. A. Gordon, and Z. Yao. 1996. The microsomal triglyceride transfer protein facilitates assembly and secretion of apolipoprotein B-containing lipoproteins and decreases cotranslational degradation of apolipoprotein B in transfected COS-7 cells. J. Biol. Chem. 271: 14124-14133.
64. Du, E. Z., S. Wang, H. J. Kayden, R. Sokol, L. K. Curtiss, and R. A. Davis. 1996. Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia. J. Lipid Res. 37: 1309-1315.
65. Wetterau, J. R., L. P. Aggerbeck, M. Bouma, C. Eisenberg, A. Munck, M. Hermier, J. Schmitz, G. Gay, D. J. Rader, and R. E. Gregg. 1992. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 258: 999-1001.
66. Sharp, D., L. Blinderman, K. A. Combs, B. Kienzie, B. Ricci, K. Wager-Smith, C. M. Gil, C. W. Turck, M. Bouma, D. J. Rader, L. P. Aggerbeck, R. E. Gregg, D. A. Gordon, and J. R. Wetterau. 1993. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 365: 65-69.
67. Wetterau, J. R., R. E. Gregg, T. W. Harrity, C. Arbeeny, M. Cap, F. Connolly, C. Chu, R. J. George, D. A. Gordon, H. Jamil, K. G. Jolibois, L. K. Kunselman, S. Lan, T. J. Maccagnan, B. Ricci, M. Yan, D. Young, Y. Chen, O. M. Fryszman, J. V. H. Logan, C. L. Musial, M. A. Poss, J. A. Robl, L. M. Simpkins, W. A. Slusarchyk, R. Sulsky, P. Taunk, D. R. Magnin, J. A. Tino, R. M. Lawrence, J. K. Dickson, Jr., and S. A. Biller. 1998. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science. 282: 751-754.
68. Wilcox, L. J., P. H. R. Barrett, R. S. Newton, and M. W. Huff. 1998. The ACAT inhibitor CI-1011 inhibits apoB secretion in HepG2 cells: an effect associated with enhanced rapid intracellular degradation and decreased MTP expression. Circulation. 98: 1-389 (Abstract)
69. Bocan, T. M. A., W. S. Rosebury, and S. B. Mueller. 1997. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit lesion formation in the rabbit. Atherosclerosis. 134: 120-121. (Abstract)